![]() | Michael Kunz |
Prominent publications by Michael Kunz
Efficacy and safety of oral alitretinoin in severe oral lichen planus – results of a prospective pilot study
[ PUBLICATION ]
BACKGROUND: Patients with severe oral lichen planus refractory to standard topical treatment currently have limited options of therapy suitable for long-term use. Oral alitretinoin (9-cis retinoic acid) was never systematically investigated in clinical trials, although case reports suggest its possible efficacy.
OBJECTIVES: To assess the efficacy and safety of oral alitretinoin taken at 30 mg once daily for up to 24 weeks in the treatment of severe oral lichen planus refractory to ...
Known for Lichen Planus | Efficacy Safety | Followup Period | Retinoid Receptors | Administration Oral |
BACKGROUND: There is a medical need for new drugs in patients with BRAF wild-type metastatic melanoma. Pazopanib is a multitarget tyrosine kinase inhibitor with antitumour and antiangiogenic activity.
OBJECTIVES: The primary aim was to investigate the metabolic response to pazopanib monotherapy and pazopanib plus paclitaxel in patients with BRAF wild-type melanoma. Secondary end points were the early cytokine and chemokine profiles and histological findings.
METHODS: Pazopanib (400 mg ...
Known for Patients Melanoma | Skin Neoplasms | Cytokine Chemokine | Combined Chemotherapy | Median Progression |
Acral lentiginous melanoma (ALM) is a unique histopathological subtype of melanoma with a poorer prognosis than other cutaneous melanomas. This study aims to evaluate the clinicopathological characteristics, metastatic pattern, prognostic factors, response to systemic therapy, and overall survival (OS) of ALM in a White population. This is a retrospective study of patients who were diagnosed and/or treated for ALM at the Department of Dermatology of the University Hospital Zurich, ...
Known for Acral Lentiginous Melanoma | Systemic Therapy | Alm Patients | Breslow Thickness | Skin Neoplasms |
Flare-Up of Rheumatoid Arthritis by Anti-CTLA-4 Antibody but Not by Anti-PD1 Therapy in a Patient with Metastatic Melanoma
[ PUBLICATION ]
A 47-year-old female patient with rheumatoid arthritis (RA) treated with methotrexate, was diagnosed with metastatic melanoma. After surgical removal of the tumor, the patient started treatment with ipilimumab while methotrexate was stopped. One week after initiation of ipilimumab, the patient developed typical symptoms of RA. Analgetic therapy was started. After 4 cycles of ipilimumab, melanoma progression was radiologically evident. The treatment plan was changed to pembrolizumab ...
Known for Rheumatoid Arthritis | Metastatic Melanoma |
Short‐ and long‐term effects of two emollients on itching and skin restoration in xerotic eczema
[ PUBLICATION ]
Pruritus is associated with various skin diseases, dry skin, and with it an impaired skin barrier function. The study objective was to investigate short-term and long-term effects of two emollients on symptoms and skin barrier functions in xerotic eczema. Randomized, double-blind, study enrolling females/males, with bilateral itching. Two emollients, containing lactic acid and refined almond oil with/without polidocanol were administered on left versus right body sides. Itching severity, ...
Known for Itching Severity | Dry Skin | Publication Administration | Eczema Emollients | Barrier Function |
Michael Kunz: Influence Statistics
Concept | World rank |
---|---|
itching severity | #54 |
stage alm | #54 |
Key People For Lichen Planus
Michael Kunz:Expert Impact
Concepts for whichMichael Kunzhas direct influence:Lichen planus, Metastatic melanoma, Oral lichen, Acral lentiginous melanoma, Acral lentiginous, Planus oral, Itching severity, Dry skin.
Michael Kunz:KOL impact
Concepts related to the work of other authors for whichfor which Michael Kunz has influence:Sensitive skin, Lichen planus, Acral melanoma, Topical dexamethasone, Regulatory capacity, Polymyalgia rheumatica, Emollient products.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |